Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

This press release is a paid market commentary distributed by a third party on behalf of Helus Pharma; it briefly summarizes prior announcements from several biotech firms including Compass Pathways. Compass Pathways is noted for granting 157,000 stock options and 74,700 restricted share units to seventeen newly hired non-executive employees under its 2026 Inducement Plan on June 1.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.